Alumis(us:ALMS)
10.05
+17.68%
Updated on 2025-04-04
Open:8.48
Close:10.05
High:10.49
Low:8.48
Prev Close:8.54
Volume:839605.00
Turnover:8.15M
Turnover Ratio:1.54%
Shares:54.41M
MarketCap:546.79M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 29 | 28575030 | 55.12% | 29 | 0 | 0 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Ayurmaya Capital Management Company, Lp | 10645965 | 20.53% | 10645965 | |
| 2024-06-30 | Foresite Capital Management V, Llc | 5584887 | 10.77% | 5584887 | |
| 2024-06-30 | Venbio Partners Llc | 2826048 | 5.45% | 2826048 | |
| 2024-06-30 | Cormorant Asset Management, Lp | 2147400 | 4.14% | 2147400 | |
| 2024-06-30 | Sr One Capital Management, Lp | 1959896 | 3.78% | 1959896 | |
| 2024-06-30 | Baker Bros. Advisors Lp | 1562500 | 3.01% | 1562500 | |
| 2024-06-30 | Yu Fan | 789618 | 1.52% | 789618 | |
| 2024-06-30 | Omega Fund Management, Llc | 653225 | 1.26% | 653225 | |
| 2024-06-30 | Ally Bridge Group (Ny) Llc | 618750 | 1.19% | 618750 | |
| 2024-06-30 | Morgan Stanley | 375000 | 0.72% | 375000 |
About
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Address:280 East Grand Avenue
Website:http://www.alumis.com
Market Movers